Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung by Lugo, Roberto et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Heterotypic paracrine signaling drives fibroblast senescence 
and tumor progression of large cell carcinoma of the lung
Roberto Lugo1, Marta Gabasa1, Francesca Andriani2, Marta Puig1,3, Federica 
Facchinetti2, Josep Ramírez4, Abel Gómez-Caro5, Ugo Pastorino6, Gemma Fuster6,7, 
Isaac Almendros1, Pere Gascón3,7, Albert Davalos8, Noemí Reguart3,7, Luca Roz2, 
Jordi Alcaraz1,9
1Unit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine, Universitat de Barcelona, Barcelona, 
Spain
2Tumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale 
dei Tumori INT, Milano, Italy
3Medical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain
4Anatomopathology Unit, Hospital Clínic de Barcelona, Barcelona, Spain
5Thoracic Surgery Unit, Hospital Clínic de Barcelona, Barcelona, Spain
6Thoracic Surgery Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
7Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
8Buck Institute for Age Research, Novato, CA, US
9CIBER de Enfermedades Respiratorias, Madrid, Spain
Correspondence to: Jordi Alcaraz, email: jalcaraz@ub.edu
Keywords: lung cancer, large cell carcinoma, cancer associated fibroblast, senescence, invasion
Received: November 09, 2015    Accepted: June 12, 2016    Published: June 30, 2016
ABSTRACT
Senescence in cancer cells acts as a tumor suppressor, whereas in fibroblasts 
enhances tumor growth. Senescence has been reported in tumor associated 
fibroblasts (TAFs) from a growing list of cancer subtypes. However, the presence 
of senescent TAFs in lung cancer remains undefined. We examined senescence 
in TAFs from primary lung cancer and paired control fibroblasts from unaffected 
tissue in three major histologic subtypes: adenocarcinoma (ADC), squamous cell 
carcinoma (SCC) and large cell carcinoma (LCC). Three independent senescence 
markers (senescence-associated beta-galactosidase, permanent growth arrest and 
spreading) were consistently observed in cultured LCC-TAFs only, revealing a selective 
premature senescence. Intriguingly, SCC-TAFs exhibited a poor growth response in 
the absence of senescence markers, indicating a dysfunctional phenotype rather 
than senescence. Co-culturing normal fibroblasts with LCC (but not ADC or SCC) 
cancer cells was sufficient to render fibroblasts senescent through oxidative stress, 
indicating that senescence in LCC-TAFs is driven by heterotypic signaling. In addition, 
senescent fibroblasts provided selective growth and invasive advantages to LCC cells 
in culture compared to normal fibroblasts. Likewise, senescent fibroblasts enhanced 
tumor growth and lung dissemination of tumor cells when co-injected with LCC cells in 
nude mice beyond the effects induced by control fibroblasts. These results define the 
subtype-specific aberrant phenotypes of lung TAFs, thereby challenging the common 
assumption that lung TAFs are a heterogeneous myofibroblast-like cell population 
regardless of their subtype. Importantly, because LCC often distinguishes itself in 
the clinic by its aggressive nature, we argue that senescent TAFs may contribute to 
the selective aggressive behavior of LCC tumors.
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INTRODUCTION
Non-small cell lung cancer (NSCLC) is the most 
frequent type of lung cancer and includes three major 
histologic subtypes: adenocarcinoma (ADC), squamous 
cell carcinoma (SCC) and large cell (undifferentiated) 
carcinoma (LCC), which account for ~40%, 30% and 5% 
of patients, respectively [1, 2]. Because all these NSCLC 
subtypes are epithelial in origin, most previous studies 
have focused on neoplastic epithelial cells. However, it is 
increasingly acknowledged that the aberrant tumor stroma 
that surrounds cancer cells supports cancer initiation, 
growth, stemness, invasion, metastasis and even resistance 
to therapies [3–5]. Accordingly, there is growing interest 
in understanding the molecular mechanisms underlying 
the tumor-promoting properties of stromal cells and in 
developing therapies targeting tumor-stroma interactions.
Tumor associated fibroblasts (TAFs) are frequently 
the most abundant cell type within the stromal 
microenvironment [3, 5]. Because the stroma in NSCLC 
and many other solid tumors is desmoplastic, the most 
common TAF phenotype is the myofibroblast-like, which 
is roughly characterized intracellularly by expression of 
alpha smooth muscle actin (α-SMA) and extracellularly 
by increased deposition of collagen and other fibrotic 
extracellular matrix (ECM) components [3, 6, 7]. 
Intriguingly, in addition to a myofibroblast-like phenotype, 
few recent studies have observed TAFs with a senescent 
phenotype in some types of breast, oral, liver and ovarian 
tumors [8–11].
A major hallmark of senescent cells is that they 
exhibit an irreversible growth arrest, yet they remain viable 
and metabolically active [12, 13]. In the context of cancer, 
a large body of work indicates that senescence acts as a 
physiologic protection against cancer cell expansion [5, 
14]. In contrast, there is growing evidence that senescence 
in fibroblasts stimulates cancer cell proliferation in culture 
and tumor growth in vivo [8, 9, 13, 15–17]. Given their 
tumor-promoting effects, examining senescence in TAFs 
is drawing increasing attention. However, the presence 
and physiopathological relevance of senescent TAFs in 
NSCLC remains unknown.
To address this gap of knowledge, we examined 
common markers of senescence in primary TAFs from the 
3 major NSCLC subtypes: ADC, SCC and LCC. Given 
the difficulties in gathering LCC-TAFs owing to the 
lower prevalence of LCC compared to the other subtypes, 
primary fibroblasts from 2 independent cell collections 
were used. We found an enrichment in myofibroblast-like 
TAFs regardless their histologic subtype, yet senescence 
was observed in LCC-TAFs only. Likewise, co-culture 
of normal lung fibroblasts with LCC (but not ADC or 
SCC) cells was sufficient to induce senescence, and this 
induction was mediated through oxidative stress. Of 
note, senescent fibroblasts provided growth and invasive 
advantages to LCC cells in culture and in vivo beyond 
those provided by control (non-senescent) fibroblasts, 
strongly supporting that they are essential contributors to 
the aggressive nature of LCC tumors.
RESULTS
Lung TAFs exhibit a myofibroblast-like 
phenotype regardless of their histological 
subtype, whereas senescence is restricted to 
LCC-TAFs
TAFs from the two major NSCLC subtypes 
(ADC, SCC) and other solid tumors exhibit an 
activated/myofibroblast-like phenotype in culture and 
in vivo [7, 18, 19]. Here we extended these observations 
by showing that LCC-TAFs are also activated and exhibit a 
statistically significant 3-fold increase in α-SMA expression 
with respect to paired CFs similar to that observed in 
ADC- and SCC-TAFs as shown by immunofluorescence 
analysis (Figure 1A, 1B). These results indicate that the 
myofibroblast-like phenotype is ubiquitous in NSCLC. In 
contrast, the percentage of fibroblasts positive for beta-
galactosidase activity at pH 6, which is a widely used 
senescence marker [13], was much higher and statistically 
significant in TAFs compared to CFs from LCC patients 
only (Figure 1C, 1D and Supplementary Figure S1). 
Likewise, TAFs from LCC patients from 2 independent 
collections had percentages of senescence-associated beta-
galactosidase activity positive (SA-βgal+) cells much higher 
than a ~3% consensus background [8, 20, 21]. Such high 
percentages of SA-βgal+ cells were found in LCC patients 
irrespective of their neuroendocrine status (Supplementary 
Table S1). In contrast, SA-βgal staining was largely absent 
(<< 3%) in CFs irrespective of their subtype, and reached 
percentages beyond background in only 20% and 10% of 
ADC- and SCC-TAFs, respectively (Figure 1C, 1D and 
Supplementary Table S1).
To further confirm the LCC-TAF-specific 
senescence enrichment, two additional senescence 
markers were examined: permanent growth arrest 
and enlarged spreading [12]. Cell cycle analysis by 
flow cytometry revealed that LCC-TAFs failed to exit 
growth arrest upon stimulation with 10% FBS compared 
to 0% FBS. Likewise, SCC-TAFs failed to enter into 
the cell cycle upon serum stimulation (Figure 1E–1F 
and Supplementary Figure S1). However, it is worth 
noting that we recently reported a marked mitogenic 
activity in SCC-TAFs in the absence of exogenous 
growth factors [18] that, in line with the lack of SA-
βgal positivity, indicates that serum desensitization in 
SCC-TAFs is indicative of fibroblast dysfunction rather 
than senescence. In contrast, the percentage of growth 
arrested cells stimulated with 10% FBS drop by ~20% 
in CFs, and slightly less in ADC-TAFs (Figure 1F). In 
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addition, LCC-TAFs exhibited a median spreading more 
than two-fold larger than all other groups (Figure 1G), 
in agreement with previous observations on senescent 
fibroblasts [13]. Therefore, all these data indicate that 
lung TAFs in culture are enriched in senescent cells 
selectively in LCC patients. Moreover, because TAFs 
from all subtypes were equally used at low passages, 
senescence in LCC-TAFs is likely to be indicative of 
premature aging rather than replicative exhaustion [12].
Selective paracrine signaling with LCC cells is 
sufficient to “educate” normal lung fibroblasts to 
become senescent
Tumor progression is increasingly regarded as 
the outcome of the aberrant co-evolution of both cancer 
and stromal cells through heterotypic signaling [3]. In 
line with this co-evolution framework, we examined 
whether paracrine interactions between LCC cells and 
Figure 1: Analysis of myofibroblast and senescence markers in primary lung fibroblasts from major NSCLC subtypes 
(ADC, SCC and LCC). A. Representative fluorescence images of α-SMA stainings of cultured CFs and TAFs from a randomly selected 
patient of each histologic subtype. Patient number is indicated in the bottom-left of each image. Scale bar here and thereafter, 50 μm. B. 
Average fold α-SMA fluorescence intensity per cell of TAFs with respect to paired CFs for each subtype (6 ADC, 8 SCC, 3 LCC). Data 
shown as mean ± SE. C. Representative phase contrast images of SA-βgal stainings of cultured CFs and TAFs from a randomly selected 
patient of each histologic subtype. SA-βgal+ fibroblasts appear in blue. More images are shown in Supplementary Figure S1. D. Box-plot 
of the percentage of SA-βgal+ fibroblasts in CFs and TAFs for each subtype from two independent collections (10 ADC, 8 SCC, 4 LCC). 
E. Average percentage of growth arrested fibroblasts (G0/G1 of the cell cycle) in CFs and TAFs for each subtype (4 ADC, 4 SCC, 3 LCC) 
cultured with 0% and 10% FBS. F. Average relative change in arrested fibroblasts at 10% versus 0% FBS computed from the data in G. All 
pair-wise comparisons were performed with respect to CFs except in (E). Mann–Whitney rank sum test was used in (D). *, P < 0.05; **, 
P < 0.01; ***, P < 0.005 here and thereafter.
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cancer “naive” human lung fibroblasts (i.e. from non-
malignant pulmonary tissue) was sufficient to induce 
senescence in the latter cells. For this purpose, normal 
human lung CCD-19Lu fibroblasts were co-cultured with 
three cancer cell lines from LCC patients (H460, H661 
and H1299) in Transwells to enable indirect heterotypic 
paracrine signaling as outlined in Figure 2A. SA-βgal+ 
percentages larger than background were found in CCD-
19Lu fibroblasts co-cultured with all LCC cell lines, with 
the highest percentage observed in H460 (Figure 2B–2C 
and Supplementary Figure S2). In contrast, percentages 
of SA-βgal+ fibroblasts comparable to the negative 
(Bare Transwell insert) control were found in fibroblasts 
co-cultured with a panel of ADC (A549, H522) and SCC 
(H520, SK-MES-1) cell lines (Figure 2C). In agreement 
with these observations, CCD-19Lu fibroblasts remained 
growth arrested upon stimulation with 10% FBS compared 
to 0% FBS after 9 days of co-culture with LCC cells, but 
not with either ADC, SCC cell lines or no cancer cells 
(Bare) (Figure 2D–2E). Interestingly, normal fibroblasts 
co-cultured with the SCC cell line SK-MES-1 exhibited 
a very modest decrease in growth arrested cells similar 
to that found in SCC-TAFs, revealing that SK-MES-1 is 
a suitable cell line to study abnormal SCC cell-stromal 
interactions. Moreover, positive markers of senescence 
(i.e. SA-βgal and permanent growth arrest) were observed 
in primary CFs from a randomly selected LCC patient 
(P29) co-cultured with LCC cells but not with ADC cells 
Figure 2: Analysis of senescence markers in normal (cancer-naive) lung fibroblasts co-cultured with lung cancer 
cell lines derived from ADC, SCC and LCC patients. A. Outline of the Transwell-based co-cultures. B. Representative phase 
contrast images of SA-βgal stainings of CCD-19Lu fibroblasts co-cultured with a panel of lung cancer cell lines. More images are shown 
in Supplementary Figure S2. C. Average percentage of SA-βgal+ CCD-19Lu fibroblasts co-cultured with a panel of lung cancer cell 
lines. Bare Transwell inserts were used as negative control. All pair-wise comparisons were performed with respect to Bare. D. Average 
percentage of growth arrested CCD-19Lu fibroblasts co-cultured with a panel of lung cancer cell lines with 0% or 10% FBS. E. Average 
relative changes in growth arrested cells computed from data in (D) as in Figure 1G.
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(Supplementary Figure S3). These results indicate that 
heterotypic paracrine signaling between LCC cells and 
normal lung fibroblasts is sufficient to induce selectively a 
senescent phenotype in the latter that is reminiscent to that 
found in LCC-TAFs.
LCC cells induce fibroblast senescence through 
oxidative stress but not TGF-β signaling
Premature fibroblast senescence has been associated 
with oxidative stress in chronic wounds and in TAFs from 
selected cancer subtypes [8, 9, 22]. In addition, the pro-
senescent effects of oxidative stress in TAFs have been 
connected recently with long-term exposure to TGF-β1 
in oral SCC [8]. To examine the involvement of these 
mechanisms in LCC-TAFs, we first co-cultured H460 LCC 
cells with CCD-19Lu fibroblasts in the presence of increasing 
doses of the antioxidant n-acetyl cysteine (NAC) and 
found a dose-dependent reduction of SA-βgal+ fibroblasts 
(Figure 3A). Alternatively, inducing oxidative stress in 
CCD-19Lu fibroblasts directly with H2O2 or indirectly with 
the chemoterapeutic DNA damaging drug bleomycin (BLM) 
[17, 23] was sufficient to induce a percentage of SA-βgal+ 
cells comparable to that induced upon co-culture with H460 
cells (Figure 3B-3C). In contrast, daily exposure of CCD-
19Lu fibroblasts to TGF-β1 -continuously or intermitently for 
4h/day as in [8]- for 2 weeks failed to increase the percentage 
of SA-βgal+ cells beyond background (Figure 3D). Likewise, 
co-culturing H460 cells with CCD-19Lu fibroblasts in the 
presence of the TGF-β pathway inhibitor SB505124 failed 
to prevent senescence induction in fibroblasts co-cultured 
with H460 cells (Figure 3E). These results support that LCC 
cells induce senescence in fibroblasts through activation of 
oxidative stress. Moreover they reveal that oxidative stress 
is necessary and sufficient to induce premature senescence in 
lung fibroblasts through mechanisms other than activation of 
the TGF-β pathway.
Conditioned medium from LCC-educated 
senescent fibroblasts provides growth and 
invasive advantages to LCC cells in culture
LCC is among the most aggressive NSCLC 
subtypes, for it tends to grow and spread more quickly 
Figure 3: Effect of oxidative stress and exogenous TGF-β1 on fibroblast senescence induction by LCC cells. A. Average 
percentage of SA-βgal+ CCD-19Lu fibroblasts co-cultured with H460 in the presence of increasing doses of the antioxidant NAC or vehicle. 
B, C. Average percentage of SA-βgal+ CCD-19Lu fibroblasts in response to direct or indirect oxidative stress elicited by (B) 2h treatment of 
H2O2 followed by 4 days of recovery or (C) 9 day treatment with bleomycin (BLM). D. Average percentage of SA-βgal+ CCD-19Lu fibroblasts 
daily treated with TGF-β1-continuously or intermitently for 4h/day as in [8]- for 2 weeks. E. Average percentage of SA-βgal+ CCD-19Lu 
fibroblasts co-cultured with H460 in the presence 5 μM of the TGF-β pathway inhibitor SB505124 for 9 days. All results correspond to two 
replicates from at least three independent experiments. All pair-wise comparisons were performed with respect to Bare or vehicle.
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than other subtypes [1, 24]. Given the previously reported 
protumorigenic effects of senescent fibroblasts in other 
cancer types [8, 9, 13, 15–17], and the aggressive nature 
of LCC, it is conceivable that LCC-educated senescent 
fibroblasts may provide a selective growth and/or invasive 
advantage to LCC cells. To examine this possibility, we 
first analyzed the growth of H460 LCC cells as outlined 
in Figure 4A. After 3 days of culture, conditioned 
medium (CM) from cancer-naive fibroblasts increased the 
population of H460 cells by ~35% with respect to H460 
cells cultured in their regular serum-free medium (used as 
control medium). Remarkably, CM from H460-educated 
senescent fibroblasts increased the population of H460 
cells by ~70%, i.e. twice as much as CM from cancer-
naive fibroblasts (Figure 4B). Qualitatively similar results 
were found in two independent LCC cell lines (H1299 
and H661) cultured in the same 3 conditions and in H460 
LCC cells cultured with CM from cancer-naive or H460-
educated senescent CFs from a randomly selected patient 
(P29) (Supplementary Figure S4). In contrast, H460 LCC 
cells did not increase their number when cultured with 
CM from CCD-19 fibroblasts co-cultured with A549 ADC 
cells (Supplementary Figure S4). Likewise, A549 ADC 
cells did not exhibit any significant growth advantage 
when cultured with CM from A549-educated fibroblasts 
compared to control medium, and only grew modestly 
with CM from cancer-naive fibroblasts (Figure 4C), in 
agreement with independent studies reported elsewhere 
[25].
Next, we examined the invasive capacity of cancer 
cells through reconstituted basement membrane (Matrigel) 
using a Transwell-based assay as outlined in Figure 4A. 
In agreement with the latter growth data, CM from H460 
educated senescent fibroblasts markedly enhanced the 
invasion of H460 LCC cells compared to serum-free 
control medium, and well beyond the effects induced 
by cancer-naive fibroblasts (Figure 4D). Comparable 
results were obtained in two LCC cell lines (H1299 and 
H661) (Supplementary Figure S4). In contrast, CM from 
fibroblasts provided an invasive advantage to A549 cells 
compared to control medium irrespective of the senescence 
status of the fibroblasts (Figure 4E). These findings reveal 
that soluble factors secreted by LCC-educated senescent 
fibroblasts are sufficient to elicit selective growth and 
invasive advantages to LCC cells beyond those provided 
by (non-senescent, non-activated) cancer-naive fibroblasts.
LCC-educated senescent fibroblasts provide a 
growth and dissemination advantage to LCC 
cells in vivo
The growth and invasive advantages provided by 
senescent fibroblasts to LCC cells in culture prompted us 
to examine whether such advantages could be observed 
in vivo as outlined in Figure 5A. We first confirmed 
that H460 cells in co-cultures can induce senescence of 
primary mouse skin fibroblasts derived from the same 
strain used in the in vivo assays (Supplementary Figure S6 
and Supplementary Material). H460 LCC cells exhibited a 
similarly marked tumor take and growth when co-injected 
subcutaneously into immunodeficient mice alone or with 
fibroblasts regardless the senescence status of the latter 
(Supplementary Figure S5). These observations are 
consistent with a recent study from some of us showing 
that the rapid growth and aggressive nature of H460 cells 
may override additional tumor-promoting signals from 
fibroblasts [26]. Alternatively, we used H460 LCC cells 
transfected with a miR-200c mimic (referred to as H460R), 
which are more responsive to microenvironmental signals 
in vivo than parental H460 cells [26], yet they retain 
both the ability to induce senescence when co-cultured 
with either human lung fibroblasts or primary mouse 
skin fibroblasts, and to provide growth and invasive 
advantages to LCC cells in culture (Supplementary Figure 
S6). All mice subcutaneously co-injected with H460R 
cells and senescent fibroblasts developed tumors after 40 
days of injection, and exhibited a statistically significant 
different time evolution with respect to H460R cells 
injected alone. In contrast, tumor take evolution was not 
statistically different between H460R cells co-injected 
alone or with cancer-naive fibroblasts, and increased 
similarly up to 60-70% during the 40 day observation 
period in both conditions (Figure 5B). Likewise, H460R 
cells co-injected with senescent fibroblasts elicited larger 
tumors than H460R cells injected either alone or with 
control fibroblasts as early as 25 days after injection. 
Five days later, H460R cells co-injected with control 
fibroblasts elicited also larger tumors than H460R alone, 
altough the statistical significance of such difference was 
lower (P < 0.05) than that attained when co-injecting 
with senescent fibroblasts (P < 0.005) (Figure 5C). The 
differences in tumor size between H460R injected alone 
or with control or senescent fibroblasts were reduced at 
the end of the observation period, which can be easily 
explained by the rapid growth of cancer cells compared to 
fibroblasts, and by the likely involvement of host stromal 
cells at longer times in all conditions [27].
To further assess the differential aggressiveness of 
LCC cells co-injected with senescent fibroblasts in vivo, 
we analyzed lung dissemination of tumor cells using a 
FACS-based approach recently reported by some of us 
[26]. As early as 20 days after the tumor latency seen 
in Figure 5B-5C (day 40 after injection), the percentage 
of lung disseminated tumor cells was already more than 
2-fold higher in mice bearing H460R co-injected with 
cancer-naive fibroblasts than in H460R injected alone, 
and was even ~10% higher when co-injected with 
senescent fibroblasts compared to cancer-naive fibroblasts 
(Figure 5D). Remarkably, the latter differential induction 
of lung disseminated tumor cells elicited by cancer-
naive fibroblasts was maintained and even increased up 
to 30% at 30 days after tumor latency (i.e. 50 days after 
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Figure 4: Assessment of the growth and invasive advantages provided by senescent fibroblasts to LCC cells in culture. 
A. Outline of the experimental design used to assess growth (top right) and invasion (bottom right) in cancer cells in culture stimulated with 
conditioned medium (CM) from fibroblasts co-cultured as in Figure 2A. B, C. Average cell number/field of either (B) H460 LCC cells or 
(C) A549 ADC cells cultured with different types of conditioned medium as described in (A). Results were normalized to control medium, 
and are shown as mean ± SE. D, E. Average invasion of either (D) H460 cells or (E) A549 cells induced by different types of conditioned 
medium as in (B,C) assessed by area quantification of crystal violet positive invasive cells (top images). Results were normalized to control 
medium. All results correspond to at least two replicates from three independent experiments. All pair-wise comparisons were performed 
with respect to control medium unless otherwise indicated.
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injection) in a different group of mice, and collectively 
all percentages of disseminated tumor cells rose ~3-fold 
(Figure 5E). Thus, even though cancer-naive fibroblasts 
co-injected with H460R cells stimulated markedly both 
tumor growth and lung dissemination compared to H460R 
injected alone, it is remarkable that such stimulation 
was further increased when co-injecting with senescent 
fibroblasts. These results strongly support that senescent 
fibroblasts elicit a more aggressive phenotype to H460R 
cells in vivo than normal fibroblasts, in agreement with our 
observations in culture.
DISCUSSION
Given the ubiquitous myofibroblast-like phenotype 
in the stroma of solid tumors, it is unsurprising the 
common assumption that lung TAFs are a heterogeneous 
population of myofibroblast-like cells regardless their 
Figure 5: Assessment of the growth and invasive advantages provided by senescent fibroblasts to LCC cells in vivo. 
A. Outline of the experimental design used to assess tumor growth and lung cancer cell dissemination of H460R LCC cells subcutaneously 
co-injected alone, with cancer-naive fibroblasts, or with H460-educated senescent CCD-19Lu fibroblasts into immunedeficient mice. 
B. Percentage of tumor-free flanks monitored over 40 days, i.e. tumors lower than 200 mm3. C. Tumor volume monitored over 40 days (n = 8 
tumors per condition). Data are mean ± SE. (D,E) Percentage of lung disseminated tumor cells at D. 30 and E. 50 days after injection. All pair-
wise comparisons were performed with respect to H460R injected alone. Statistical significance in (B) was assessed by log-rank test.
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histologic subtype [28, 29]. However, we recently 
challenged this assumption by reporting strikingly 
distinct responses to extracellular matrix stiffening and 
growth factor stimulation between ADC- and SCC-TAFs, 
which were associated with subtype-specific β1 integrin 
expression and FAK activity [18]. In the present study we 
expanded these observations further by reporting for the 
first time two new subtype-specific aberrant phenotypes 
in lung TAFs: (i) poor growth response in the absence 
of senescence markers in SCC-TAFs, and (ii) premature 
cellular aging or senescence in LCC-TAFs. In addition, 
we identified SK-MES-1 and H460 as suitable lung cancer 
cell lines to reprogram normal fibroblasts towards the 
acquisiton of the latter two aberrant phenotypes observed 
in SCC- and LCC-TAFs, respectively. Interestingly, similar 
aberrant phenotypes have been reported in fibroblasts from 
chronic (non-healing) wounds, and pointed as essential 
contributors to the wound chronicity [22, 30, 31]. Thus, 
our findings begin to define the subtype-specific stromal 
similarities between lung tumors and chronic wounds, 
and reveal convenient preclinical culture models to study 
subtype-specific cancer-stroma interactions in the context 
of SCC and LCC.
Epidemiologically, increased cellular senescence 
has been linked with aging [13]. However, even though 
virtually all our patients were > 55 year old, aging alone 
could not explain the selective appearance of senescent 
TAFs in LCC, for CFs from the same patients were not 
senescent. On the other hand, premature senescence in 
lung fibroblasts has been previously associated with 
cigarette smoke [21] and emphysema [32]. However, our 
selected patients were all current smokers and exhibited 
different degrees of lung emphysema, yet CFs and most 
TAFs were negative for senescence markers in ADC and 
SCC patients, indicating that the premature senescence of 
LCC-TAFs was attributed to neither cigarette smoke nor 
emphysema, but rather to LCC-specific processes.
At the mechanistic level, a large body of work 
indicates that senescence can be induced by either 
telomere-dependent or independent processes. The 
lack of senescence markers in CFs from LCC patients 
and the strong inhibition of fibroblast senescence when 
co-cultured with LCC cells in the presence of increasing 
doses of the antioxidant NAC strongly support that 
senescence in LCC-TAFs was due to a telomere-
independent process mediated by oxidative stress from 
LCC cells. In support of this interpretation, inducing 
oxidative stress in normal lung fibroblasts directly by 
H2O2 or indirectly by the DNA damage drug bleomycin 
was sufficient to render them senescent, in agreement with 
previous studies with fibroblasts from other tissue types 
[17]. Likewise, oxidative stress elicited by secreted factors 
from oral SCC cells was found necessary for senescence 
induction in normal oral fibroblasts [8]. However, the 
latter study reported that fibroblast senescence was 
selectively induced by genetically unstable (p53 deficient) 
oral SCC cells but not by wild-type p53 cells, and was 
mediated by sustained TGF-β exposure. In contrast, H460 
LCC cells induced the largest percentage of senescent 
lung fibroblasts in co-culture experiments yet they have 
wild-type p53. Conversely, most of the ADC and SCC 
cell lines used in our study have mutant p53 yet they 
failed to induce senescence in fibroblasts (Figure 2C and 
Supplementary Table S2). Likewise, long-term exposure 
to exogenous TGF-β1 alone did not induce premature 
fibroblast senescence, and inhibiting the TGF-β pathway 
in co-cultures of LCC cells with fibroblasts failed to 
prevent fibroblast senescence. These results illustrate the 
ability of LCC cells to selectively “educate” fibroblasts 
to become senescent irrespective of their p53 status, 
and reveal that such “education” is mediated, at least 
in part, through oxidative stress-dependent and TGF-β 
pathway-independent signaling. Elucidating the molecular 
mechanism by which the crosstalk between LCC cancer 
cells and fibroblasts induce oxidative stress-dependent 
senescence in fibroblasts was beyond the scope of this 
study. However, potential mechanisms include either 
direct or indirect induction of oxidative stress by extrusion 
of reactive oxygen species (ROS) or secretion of non-ROS 
signaling factors by cancer cells, respectively [8, 9].
Even though normal (pre-senescent) fibroblasts 
provided notable growth and invasive advantages to LCC 
cells in culture, such advantages were further increased by 
cancer-educated senescent fibroblasts in three independent 
LCC cell models. Likewise, the largest tumor take, tumor 
growth and lung dissemination of tumor cells in vivo were 
consistently observed when LCC cells were co-injected 
with senescent fibroblasts (Figure 4). In agreement with 
our observations, increased tumor sizes have been reported 
in xenografts of cancer cells co-injected with senescent 
compared to pre-senescent fibroblasts in other cancer cell 
models [15, 27, 33–35]. Likewise, breast cancer cells 
co-injected with fibroblasts exhibiting an autophagic/
senescent phenotype into the tail veins of nude mice 
elicited increased lung colonization compared to that 
elicited by control fibroblasts [9]. In contrast, to our 
knowledge we are the first to report enhanced tumor cell 
dissemination to the lungs from primary tumor xenografts 
using cancer cells co-injected with senescent fibroblasts. 
These observations strongly support that premature 
senescence in TAFs may potentiate the aggressive nature 
of a tumor, at least in terms of growth and dissemination, 
which is in marked contrast with the well-known tumor 
suppressive role of senescence in cancer cells [5, 14].
LCC tumors, particularly those positive for 
neuroendocrine markers, often distinguish themselves 
in the clinic by their aggressive behavior. However, the 
mechanisms underlying the aggressive features of LCC 
tumors remain fairly unknown. In this context, it is 
worth noting that protein biomarkers for senescence and 
oxidative stress in the tumor stroma have been associated 
with poor clinical outcome and drug-resistance in human 
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breast cancer patients [9, 36]. On the other hand, we found 
a selective premature senescence in LCC-TAFs in culture, 
and that senescent fibroblasts provide growth and invasive 
advantages to LCC cells in culture and in vivo beyond 
those provided by non-senescent fibroblasts. Based 
on these lines of evidence, it is tempting to speculate 
that senescent TAFs may support, at least in part, the 
aggressive nature of LCC tumors.
Defining how senescent fibroblasts contribute to 
disease progression is drawing increased attention not only 
in cancer, but also in chronic wounds and other diseases 
[13, 22]. Elucidating the specific tumor promoting 
mechanisms of senescent TAFs in LCC was beyond the 
scope of our work. However, previous studies have shown 
that senescent fibroblasts exhibit a secretory phenotype or 
SASP enriched in factors involved in numerous processes 
including epithelial growth, ECM degradation, and 
inflammation [13, 37]. Our in vivo data are consistent 
with the first two processes. Likewise, additional 
support for an important role of growth factors and ECM 
degrading enzymes secreted by senescent fibroblasts in 
tumor progression has been reported elsewhere [17, 27, 
34]. Thus, future studies are warranted to examine the 
biological causes and clinical implications of the selective 
premature senescence of LCC-TAFs revealed in this study.
MATERIALS AND METHODS
Lung tissue samples and primary human lung 
fibroblasts
Primary fibroblasts were obtained from two 
independent collections. In the first collection, tissue 
samples were gathered from 19 resected lung specimens 
from early stage NSCLC patients at the Hospital Clinic 
de Barcelona (HCB, Spain) (8 ADC, 8 SCC, 3 LCC). 
The study was approved by the Ethics Committees 
of the HCB and the Universitat de Barcelona, and all 
patients gave their informed consent. Selected patients 
were male, chemo-naïve, Caucasian, ≥ 55 years old, and 
current smokers. A fraction of each tissue sample was 
paraffin-embedded, and the remaining was used to isolate 
fibroblasts by outgrowth of tissue explants [38]. Samples 
from tumor and paired tumor-free lung parenchyma 
were used to obtain tumor associated fibroblasts (TAFs) 
and control fibroblasts (CFs), respectively. In the 
second collection, tumor samples were gathered from 
5 resected NSCLC patients at the Fondazione IRCCS 
Istituto Nazionale dei Tumori in Milano (INT, Italy) 
(2 ADC, 2 SCC, 1 LCC), with the approval of the Ethics 
Committee of the Fondazione IRCCS INT and with the 
informed patient consent. The patient selection criteria 
were similar to those used in the first collection, and 
fibroblasts were isolated by collagenase digestion [39]. 
The mesenchymal nature of the fibroblasts was confirmed 
by their positive and negative immunofluorescence 
staining with mesenchymal and epithelial/hematopoietic 
antibodies, respectively (more details in Supplementary 
Material). A summary of clinical patient data is shown in 
Supplementary Table S1.
Cell culture
The human fibroblast cell line CCD-19Lu obtained 
from normal pulmonary tissue (ATCC) and primary 
fibroblasts were maintained in DMEM-based fibroblast 
culture medium described elsewhere [18, 39]. Fibroblasts 
were used up to either passage 10 (CCD-19Lu) or 6 
(primary) to prevent replicative senescence [28]. All 
experiments with fibroblasts alone were carried out on 
tissue culture plastic substrata coated with 0.1 mg/ml 
collagen-I solution (Millipore) overnight at 4ºC. Unless 
otherwise indicated, fibroblasts were seeded at 3.3×103 
cells/cm2 in all mono-culture experiments. In some 
experiments, fibroblasts were daily exposed to 4 ng/ml 
recombinant human TGF-β1 (R&D Systems) continuously 
or intermitently for 4h/day up to 2 weeks. In other 
experiments, fibroblasts were treated with 0.15-0.3 mM 
H2O2 (Sigma) for 2h to induce oxidative stress, washed and 
maintained for 4 days as reported elsewhere [17]. For SA-
βgal experiments, fibroblasts were seeded on 6-well plates 
and maintained in serum-free fibroblast culture medium 
for 3 days. In some experiments, CCD-19Lu fibroblasts 
were treated with 50 mU/mL bleomycin (Sigma) for 
10 days, refreshing the bleomycin containing medium 
on alternating days. For flow cytometry experiments, 
fibroblasts were seeded in fibroblast culture medium for 
24h and maintained either in 0% FBS (serum-free) or 10% 
FBS medium for 5 days with a media change at day 3. 
For immunofluorescence measurements, fibroblasts were 
seeded at 8×103 cells/cm2 on 8-well chamber slides (BD) 
in serum-free fibroblast culture medium for 3 days.
Co-culture experiments were carried out with a panel 
of lung cancer cell lines (ATCC, Manassas) originally 
derived from either ADC (A549, H522), SCC (H520, SK-
MES-1) and LCC (H460, H661, H1299) patients (ATCC), 
and were used up to passage 10. Their p53 status is shown 
in Supplementary Table S2. Cancer cells were maintained 
in RPMI-1640 medium supplemented with 10% of FBS 
(Gibco), 50 IU/mL penicillin, 50 μg/mL streptomycin, 
2.5 μg/mL amphotericin B (Sigma), 0.01 M Hepes and 
1 mM L-glutamine (Gibco) (referred to as epithelial 
culture medium). For some experiments, H460 cells were 
transfected with a miR-200c mimic to render them more 
epithelial-like [40] and responsive to microenvironmental 
signals as recently reported by some of us [26]. For this 
purpose, H460 cells were transiently transfected with 50 
nmol/L of the miR-200c mimic pre-miR-200c (Ambion) 
with Lipofectamine 2000 (Invitrogen), and are referred to 
as H460R thereafter.
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Heterotypic co-culture of cancer cells and 
fibroblasts
Indirect co-culture experiments were conducted 
in Transwell culture plates with inserts (6 Transwell 
plate, 0.4 µm pore size; Corning). Fibroblasts from non-
malignant tissue (either CCD-19Lu or primary CFs) were 
seeded in a collagen-coated lower Transwell compartment 
at 5.2×103 cells/cm2 in serum-free fibroblast culture 
medium. Cancer cells were seeded on the Transwell 
insert at 2.2×104 cells/cm2 in serum-free epithelial culture 
medium at equal volume than fibroblasts for 9-10 days. 
Bare (cell-free) inserts were used as negative controls. 
Culture medium was replaced twice weekly. In some 
co-culture experiments, cells were either daily treated with 
the antioxidant n-acetyl cysteine (NAC, Sigma) or vehicle 
or every 2-3 days with the inhibitor of the TGF-β pathway 
SB505124 (5 μM, Sigma) [41]. For flow cytometry 
experiments, replicate co-cultures were maintained with 
20% FBS epithelial culture medium to render a final 10% 
FBS concentration upon mixing with fibroblast medium.
Conditioned medium (CM)
Fibroblasts were co-cultured in Transwells with 
either bare or cancer cell seeded inserts as described 
above, which were referred to thereafter as cancer-naive 
or cancer-educated fibroblasts, respectively. After 9 days, 
inserts were removed, and fibroblasts were maintained for 
4 additional days in serum-free fibroblast culture medium. 
Afterwards, the fibroblast condition medium (CM) was 
collected, centrifuged to remove suspended cells, and 
stored at -20ºC until use.
Immunofluorescence
Immunofluorescence detection and quantification 
of α-SMA in cultured fibroblasts were carried out as 
described elsewhere [18, 19].
Senescence-associated beta-galactosidase activity 
(SA-βgal)
SA-βgal activity at pH 6.0 was detected following 
a slightly modified protocol [20]. In brief, fibroblasts 
were fixed with 4% PFA (Sigma) for 5 min at RT and 
incubated with SA-βgal staining solution containing 0.2 
M citric acid/sodium phosphate buffer (pH 6.0), 100 mM 
potassium ferricyanide, 100 mM potassium ferrocyanide, 
5 M sodium chloride, 2 M magnesium chloride, and 
20 mg/mL X-gal (5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside) (Sigma) at 37 ºC in a stove for 
~12h. For each experimental condition, 9 randomized 
images were obtained with a phase-contrast microscope 
(Nikon) provided with a F-145C2 Marlin color camera 
(Allied Vision Technologies) using Metamorph software 
(Molecular Devices) and a ×20 objective. The percentage 
of SA-βgal+ (blue) cells was assessed for each image, and 
averaged for each experimental condition. In average, 
~800 fibroblasts were counted per condition.
Flow cytometry
Cell cycle analysis was performed from DNA 
histograms of single cells obtained by flow cytometry 
(LSRFortessa, BD Biosciences) as reported elsewhere 
[18]. The percentages of arrested fibroblasts (i.e. cells in 
G0/G1) were assessed with FACSDiva Software v6.1.3 
(BD).
Cell spreading
Phase contrast images acquired to assess SA-β-
gal were also used to assess cell spreading by manually 
outlining the contour of individual cells with Image J, 
and averaging the corresponding spreading areas for each 
patient.
Cell density
Cancer cells were plated at 1.1×103 cells/cm2 in 6 
well plates and grown in 2 ml of a 1:1 mixture of CM 
and serum-free epithelial culture medium for 3 days. A 
1:1 mixture of serum-free fibroblast/epithelial culture 
medium was used as (basal) control medium. Cell density 
was computed as described [18]. In brief, cells were 
fixed with 4% PFA and their nuclei counterstained with 
Hoechst 33342 (Molecular Probes). Fluorescent nuclei 
were imaged and counted with Image J. Cell density 
was assessed as the average nuclear density/image, and 
normalized to the value obtained with control medium.
Invasion
Cancer cell invasion was assessed with a slightly 
modified Transwell-based assay [37], and performed with 
Transwell culture plates with filter-inserts (24 Transwell plate, 
8 µm filter pore size; Merck Millipore). Matrigel (BD) was 
diluted in serum-free epithelial culture medium (1:5). Filters 
were coated with 50 μl diluted Matrigel and incubated for 
2h at 37ºC. Cancer cells were immediately seeded on the 
Matrigel-coated filter-inserts as 0.2×103 cells/cm2 in serum-
free epithelial culture medium. CM or control medium (see 
cell density) was added to the lower Transwell compartment. 
After 24h, cells were fixed with 100% methanol for 15 min, 
and incubated with 0.5% crystal violet (Sigma) for 30 min at 
RT. Cells on the apical side of the filter-inserts were scraped 
off. Cells that had invaded into the lower side of the filter were 
visualized by a phase-contrast microscope provided with a 
color camera and a ×10 objective. Images of 9 random fields 
were obtained per condition. Crystal violet positive area per 
image was assessed using color thresholding with Image J. 
Invasion was computed as the average crystal violet positive 
area/image, and normalized to that obtained in control medium.
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In vivo tumorigenecity assay
Tumorigenic assays were carried out using CD1-nude 
female mice (Charles River Laboratories) 5-10 weeks old, 
which were maintained and manipulated using protocols 
approved by the Ethics Committee of the Fondazione 
IRCCS INT according to EU Directive 2010/63/EU. H460 
or H460R cells (1×103) suspended in 0.1 mL Matrigel 
(BD Biosciences) were subcutaneously injected into both 
flanks alone or with CCD-19Lu fibroblasts (3×103) that 
exhibited either a normal or a senescent phenotype (n = 
8/cell condition). Senescence was induced by co-culture 
with H460 cells as described above. Tumor growth was 
monitored for 40 days by assessing tumor volume as 
0.5×width2×length [35]. At the end of the observation 
period or when tumors reached at least 300 mm3, lungs were 
removed and dissociated for further analysis.
In vivo tumor dissemination
To assess tumor dissemination in tumor-bearing mice, 
lungs from randomly selected animals (n = 4/cell condition) 
were removed at either 40 or 50 days after injection as 
described elsewhere [39], finely minced using a scalpel 
blade, enzymatically digested for 1h at 37 °C with Tumor 
Dissociation Kit in Gentle Macs Octo Dissociator (Miltenyi 
Biotec) and filtered through a 100 µm cell strainer (BD 
falcon). Red blood cells were removed by Lysing Buffer 1X 
(Becton Dickinson). Disseminated human tumor cells were 
identified by flow cytometry using a negative gating strategy 
to exclude both 7-aminoactinomycin D (7-AAD+ non viable) 
cells and mouse H2K+ cells as recently reported by some 
of us [39]. In brief, lung cell suspensions were washed and 
incubated in staining solution containing 1% BSA, 2 mM 
EDTA, PerCP-eFluor 710 anti-mouse MHC class I (dilution 
1:50, e-Bioscence) and 7-AAD viability staining solution 
(dilution 1:10, e-Bioscence). Fluorescence was detected with 
a flow cytometer in the far red range using a 650 nm long-
pass filter. Final amount of lung disseminated tumor cells was 
expressed as percentage of 7-AAD and mouse H2K negative 
cells. This approach was able to specifically detect as few as 
103 single human cells in murine lungs [39].
Statistical analysis
Two group comparisons were performed with 
Student’s t-test (SigmaPlot) unless otherwise indicated. 
Statistical significance was assumed at P<0.05. All data 
shown are mean ± SD unless otherwise specified.
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